INmune Bio's CORDStrom™ Platform Patent Advances in US, Securing Potential Protection Until 2045
INMB sits 48% above its 52-week low of $1.09.
Summary
INmune Bio has advanced its CORDStrom™ platform patent application into the U.S. national phase, a critical step following a favorable international written opinion on its patentability. This development builds on recent positive UK regulatory feedback for the CORDStrom™ drug. If granted, this foundational patent family is projected to provide exclusive commercial protection for the platform and its lead drug Ebstrocel until at least 2045. This significantly de-risks a core asset and enhances the long-term valuation and commercial runway for the small-cap biotech.
At the time of this announcement, INMB was trading at $1.61 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $43.3M. The 52-week trading range was $1.09 to $3.24. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.